AFRM three-lens brief
Evidence-based stock research on AFRM. Three independent lenses — Quality, Momentum, Context — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Outperforming SPY by 30.2pp over 30 days. · P/E of 79 — priced for high growth; little margin of safety.
- Outperforming SPY by 30.2pp over 30 days.
- P/E of 79 — priced for high growth; little margin of safety.
- Analyst mean target $78.93 — 24% above current (27 analysts).
- Debt-to-equity of 258.9 — balance-sheet-heavy.
- Earnings scheduled 2026-05-07.
AFRM closed at $63.72 (+1.18%) as of 2026-04-25. Market cap: $21.23B. P/E (trailing) 78.7. Positives: outperforming SPY by 30.2pp over 30 days.; analyst mean target $78.93 — 24% above current (27 analysts).. Concerns: p/E of 79 — priced for high growth; little margin of safety.; debt-to-equity of 258.9 — balance-sheet-heavy.. Last quarter: Revenue $1.12B, net income $129.59M, free cash flow $457.45M. Watching for: 2026-05-07 earnings release (12 days out).
Why three lenses on AFRM, not one.
A single reasoning model has blind spots it doesn’t know about. We examine AFRMacross Quality (fundamentals), Momentum (price action and sentiment), and Context (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://clearpathinvest.app/embed/AFRM" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath AFRM brief"></iframe>